Select Language

Dr. Gaurav Kharya

Doctor photo
Doctor

Dr. Gaurav Kharya

Senior Consultant – Paediatric Oncology & Haematology • Indraprastha Apollo Hospital

About Dr. Gaurav Kharya
• Position: Senior Consultant – Paediatric Oncology & Haematology
• Affiliation: Clinical Lead, Centre for BMT (Bone Marrow Transplant) & CT (Cellular Therapy); Senior Consultant, Paediatric Haematology Oncology & Immunology, Indraprastha Apollo Hospital, Delhi
Training & Expertise:
• Trained in India and abroad in Paediatric Haematology, Oncology, and BMT
• Expertise in managing paediatric blood disorders, childhood cancers, and bone marrow transplant procedures
Key Achievements:
• Performed the largest number of bone marrow transplants for Sickle Cell Disease in the country
• Developed innovative protocols for multiple transplant procedures
Academic & Research Interests:
• Strong involvement in academics and clinical research
• Focus on advanced therapies like Chimeric Antigen Receptor (CAR) T-Cell therapy
• Research in Gene Editing and Gene Therapy for inborn errors
Professional Summary:
• Recognized for combining clinical excellence with research-driven care in paediatric patients
• Dedicated to advancing treatment options for children with complex blood disorders and cancers
• Plays a leading role in developing next-generation cellular and genetic therapies for paediatric care

10.0+

Years Experience

120+

Procedures

Delhi

Location

About Dr. Dr. Gaurav Kharya

About Dr. Gaurav Kharya
• Position: Senior Consultant – Paediatric Oncology & Haematology
• Affiliation: Clinical Lead, Centre for BMT (Bone Marrow Transplant) & CT (Cellular Therapy); Senior Consultant, Paediatric Haematology Oncology & Immunology, Indraprastha Apollo Hospital, Delhi
Training & Expertise:
• Trained in India and abroad in Paediatric Haematology, Oncology, and BMT
• Expertise in managing paediatric blood disorders, childhood cancers, and bone marrow transplant procedures
Key Achievements:
• Performed the largest number of bone marrow transplants for Sickle Cell Disease in the country
• Developed innovative protocols for multiple transplant procedures
Academic & Research Interests:
• Strong involvement in academics and clinical research
• Focus on advanced therapies like Chimeric Antigen Receptor (CAR) T-Cell therapy
• Research in Gene Editing and Gene Therapy for inborn errors
Professional Summary:
• Recognized for combining clinical excellence with research-driven care in paediatric patients
• Dedicated to advancing treatment options for children with complex blood disorders and cancers
• Plays a leading role in developing next-generation cellular and genetic therapies for paediatric care

Experience Highlights

  • Credited for conducting the largest number of transplants for Sickle Cell Disease in the country.
  • Developed innovative protocols for various transplant procedures.
  • Academic and Research Interests:
  • Dr. Kharya has a keen interest in academics and research.
  • Focuses on futuristic therapies, including Chimeric Antigen Receptor T Cell therapy.
  • Researches Gene Editing/Gene Therapy for various inborn errors.
  • Dr. Gaurav Kharya is a distinguished figure in the field of Paediatric Oncology & Haematology, serving as a Clinical Lead at the Centre for BMT and CT while holding the position of Senior Consultant in Paediatric Haematology Oncology & Immunology at Indra
  • One of Dr. Kharya's notable accomplishments is his credit for performing the largest number of transplants for Sickle Cell Disease in the country. His contributions also extend to the development of innovative protocols for various transplant procedures,
  • In addition to his clinical work, Dr. Kharya is deeply involved in academics and research. He places special emphasis on pioneering therapies like Chimeric Antigen Receptor T Cell therapy, which holds promise for the future of cancer treatment. Furthermor
  • Dr. Gaurav Kharya's commitment to advancing medical knowledge and providing cutting-edge treatments underscores his dedication to improving the lives of children with complex blood disorders and cancers.